Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.

doi:10.1111/ejh.14304

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.

European journal of haematology - 1 Feb 2025

Bresser Helena, Schmoor Claudia, Grishina Olga, Pfeifer Dietmar, Thomas Johanna, Rehman Usama-Ur, Crysandt Martina, Jost Edgar, Thol Felicitas, Heuser Michael, Götze Katharina S, Schlenk Richard F, Salih Helmut R, Schittenhelm Marcus M, Heil Gerhard, Schwaenen Carsten, Müller-Tidow Carsten, Brugger Wolfram, Kündgen Andrea, de Wit Maike, Giagounidis Aristoteles, Scholl Sebastian, Neubauer Andreas, Krauter Jürgen, Bug Gesine, May Annette M, Wäsch Ralph, Duyster Justus, Döhner Konstanze, Ganser Arnold, Döhner Hartmut, Hackanson Björn, Becker Heiko, Lübbert Michael

Abstract excerpt

In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse-risk genetics, without adding toxicity. We performed a post hoc analysis to determine the predictive impact of TP53 status. Despite a nominally higher ORR, the clinically meaningful...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Leukemia, Myeloid, Acute

Share to Prognosis

Share to Treatment Outcome

Share to Tretinoin

Share to Tumor Suppressor Protein p53

Share to Valproic Acid

Source

Open in PubMed

Identifiers

PMID: 39400388
DOI: 10.1111/ejh.14304

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.PMID 39400388Read ↗

Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.Semantic proximity Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.Semantic proximity Read ↗

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.Semantic proximity Read ↗

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.Semantic proximity Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk geneticsSemantic proximity Read ↗

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsSemantic proximity Read ↗

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.Semantic proximity Read ↗

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Semantic proximity Read ↗

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Semantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.